Therapy for Hepatobiliary Cancers

Nov 10 2025
Convention Center: Ballroom C, Level 3
11:00 AM - 12:30 PM

World Class Speakers

Andrew Moon, MD, MPH
Moderator

Andrew Moon, MD, MPH

University of North Carolina
Kara Wegermann, MD
Moderator

Kara Wegermann, MD

Duke University

Description

The therapeutic options for patients with hepatobiliary cancers are expanding, and at the same time the impact of comorbidities on outcomes has become clearer.  Participants will learn about the influence of  MASLD, tumor buden and liver heatlh on treatment success; the potential of immuotherapy in HCC; and consider surgical treatment options in hepatobiliary cancers.

Journey Maps

Objectives

  • Describe the role of comorbid influences such as MASLD or liver health on treatment of HCC.
  • Evaluate immunologic, radiologic and surgical therapies for hepato-biliary cancers.